Antares Pharma (NASDAQ:ATRS) Lowered to “Hold” at BidaskClub

BidaskClub downgraded shares of Antares Pharma (NASDAQ:ATRS) from a buy rating to a hold rating in a research report sent to investors on Saturday morning, BidAskClub reports.

Separately, HC Wainwright upped their price objective on shares of Cytokinetics from $21.00 to $26.00 and gave the stock a buy rating in a research report on Monday, May 6th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $4.83.

ATRS opened at $3.02 on Friday. The company has a quick ratio of 1.90, a current ratio of 2.28 and a debt-to-equity ratio of 0.50. The company has a fifty day moving average price of $3.03. Antares Pharma has a 1 year low of $2.53 and a 1 year high of $3.96.

Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings data on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.01. The company had revenue of $23.29 million during the quarter, compared to analysts’ expectations of $17.46 million. Antares Pharma had a negative net margin of 7.91% and a negative return on equity of 17.94%. As a group, equities research analysts forecast that Antares Pharma will post -0.1 earnings per share for the current fiscal year.

In other Antares Pharma news, Director Thomas J. Garrity sold 30,000 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $2.67, for a total transaction of $80,100.00. Following the completion of the transaction, the director now directly owns 190,213 shares in the company, valued at $507,868.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.49% of the company’s stock.

Large investors have recently bought and sold shares of the business. Legal & General Group Plc grew its holdings in shares of Antares Pharma by 16.6% during the fourth quarter. Legal & General Group Plc now owns 25,244 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 3,587 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Antares Pharma by 0.4% during the fourth quarter. Northern Trust Corp now owns 1,741,602 shares of the specialty pharmaceutical company’s stock worth $4,738,000 after buying an additional 6,868 shares in the last quarter. Corrado Advisors LLC purchased a new stake in shares of Antares Pharma during the second quarter worth $26,000. Alpine Woods Capital Investors LLC purchased a new stake in shares of Antares Pharma during the first quarter worth $30,000. Finally, Enterprise Bank & Trust Co purchased a new stake in shares of Antares Pharma during the first quarter worth $45,000. Institutional investors own 42.36% of the company’s stock.

About Antares Pharma

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Further Reading: Why is momentum important to successful trading?

Analyst Recommendations for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.